NCT07656922 Scapular Muscle Activation and Shoulder Performance in Migraine
| NCT ID | NCT07656922 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ankara Yildirim Beyazıt University |
| Condition | Migraine |
| Study Type | OBSERVATIONAL |
| Enrollment | 50 participants |
| Start Date | 2026-04-01 |
| Primary Completion | 2026-07-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 50 participants in total. It began in 2026-04-01 with a primary completion date of 2026-07-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Migraine is a significant health problem due to its high prevalence and substantial contribution to disability. Individuals with migraine have been reported to exhibit myofascial trigger points, increased pain sensitivity, and altered muscle activation patterns, particularly in the trapezius muscles. As the upper and middle trapezius muscles play critical roles in scapular stability and movement, alterations in these muscles may affect scapular orientation and upper extremity function. However, studies investigating the relationship between trapezius muscle activation, scapular orientation, and upper extremity performance in individuals with migraine are limited. Therefore, this study aimed to compare trapezius muscle activation, scapular orientation, and upper extremity performance between individuals with and without migraine. We hypothesized that individuals with migraine would exhibit altered upper and middle trapezius muscle activation, impaired scapular orientation, and reduced upper extremity performance compared with healthy controls.
Eligibility Criteria
Inclusion Criteria: * Aged 18-55 years * Diagnosed with migraine by a neurologist according to the ICHD-3 criteria * Experiencing at least 3 migraine attacks per month * Willing to participate and provide written informed consent Exclusion Criteria: * Presence of other types of headache disorders * History of trauma, fracture, or surgery involving the cranio-cervical region, scapular region, or upper extremity * Presence of neurological or inflammatory rheumatic diseases * Presence of psychiatric disorders * Receiving physiotherapy or rehabilitation for migraine or the cervical, thoracic, or upper extremity regions within the past 6 months * Cognitive impairment affecting the understanding of test instructions
Frequently Asked Questions
Who can join the NCT07656922 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 55 Years, studying Migraine. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07656922 currently recruiting?
Yes, NCT07656922 is actively recruiting participants. Visit ClinicalTrials.gov or contact Ankara Yildirim Beyazıt University to inquire about joining.
Where is the NCT07656922 trial being conducted?
This trial is being conducted at Ankara, Turkey (Türkiye).
Who is sponsoring the NCT07656922 clinical trial?
NCT07656922 is sponsored by Ankara Yildirim Beyazıt University. The trial plans to enroll 50 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.